ArticleESMO real world data and digital oncology2024
Clinical trial and real-world evidence of circulating tumor DNA monitoring to predict recurrence in patients with resected colorectal cancer.
Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring.The journal of liquid biopsy · 2026Article
- ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions.OncoTargets and therapy · 2026Review
- Direct Comparison of Tumor-Informed and Tumor-Naive Circulating Tumor DNA Assays for Recurrence Detection in Early-Stage NSCLC.JTO clinical and research reports · 2026Article
- Monitoring and Assessment of Circulating Tumor DNA in Cancers Using Ultrarapid Sensitivity as an Innovative Practice.Health science reports · 2025Article
- Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer.NPJ breast cancer · 2025Article
- Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors.Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating tumor DNA (ctDNA) is a novel biomarker to predict recurrence in colorectal cancer (CRC). However, clinical validation data in underrepresented patient populations like Southeast Asians are lacking. Materials and methods: In our prospective clinical trial, 92 patients with stage I-IVA CRC and eligible for curative-intent surgery were recruited. Blood samples were collected before surgery, after surgery and during surveillance. ctDNA analysis was carried out using a personalized tumor-informed approach. Performance of ctDNA monitoring was further evaluated in a retrospective analysis of 32 patients who had commercial ctDNA testing. Results: Before surgery, the ctDNA detection rate was 91.2%, significantly higher than the carcinoembryonic antigen (CEA) elevation rate at 42.9%. At 2-4 weeks after surgery, ctDNA detection, not CEA, was significantly associated with shorter disease-free survival (DFS) [hazard ratio (HR) = 30.3, 95% confidence interval (CI) 3.3-278.9, Conclusion: Our analysis from both clinical trial and real-world data indicated that ctDNA was an independent and strong prognostic biomarker to predict recurrence in CRC. ctDNA testing could be helpful for clinical decision making by enabling personalized intervention and surveillance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.